SPR741 is primarily investigated for its potential as an antibiotic adjuvant, enhancing the effectiveness of existing antibiotics against Gram-negative bacteria. It works by disrupting the outer membrane of these bacteria, making them more susceptible to antibiotics that they would otherwise resist. This is particularly valuable in combating multidrug-resistant infections, where traditional antibiotics fail. Its application is being explored in treating infections like pneumonia, urinary tract infections, and sepsis, especially in hospital settings where resistant strains are prevalent. Research is ongoing to determine its safety and efficacy in clinical use.